medric medric
잠시만 기다려 주세요. 로딩중입니다.

Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models

Korean Journal of Physiology & Pharmacology 2019년 23권 5호 p.329 ~ 334
 ( Nam Dae-Hwan ) - Korea Institute of Toxicology Predictive Model Research Center

 ( Park Jin-Sook ) - LG Chem Ltd.
 ( Park Sun-Hyun ) - Korea Institute of Toxicology Predictive Model Research Center
 ( Kim Ki-Suk ) - Korea Institute of Toxicology Predictive Model Research Center
 ( Baek Eun-Bok ) - LG Chem Ltd.


Diabetes is associated with an increased risk of cardiovascular complications. Dipeptidyl peptidase-4 (DPP-IV) inhibitors are used clinically to reduce high blood glucose levels as an antidiabetic agent. However, the effect of the DPP-IV inhibitor gemigliptin on ischemia/reperfusion (I/R)-induced myocardial injury and hypertension is unknown. In this study, we assessed the effects and mechanisms of gemigliptin in rat models of myocardial I/R injury and spontaneous hypertension. Gemigliptin (20 and 100 mg/kg/d) or vehicle was administered intragastrically to Sprague?Dawley rats for 4 weeks before induction of I/R injury. Gemigliptin exerted a preventive effect on I/R injury by improving hemodynamic function and reducing infarct size compared to the vehicle control group. Moreover, administration of gemigliptin (0.03% and 0.15%) powder in food for 4 weeks reversed hypertrophy and improved diastolic function in spontaneously hypertensive rats. We report here a novel effect of the gemigliptin on I/R injury and hypertension.


Dipeptidyl peptidase-IV; Gemigliptin; Myocardial ischemia-reperfusion injury; Pressure-volume loop; Spontaneously hypertensive rat
원문 및 링크아웃 정보
등재저널 정보